Saniona to attend and present at several conferences in 2026

SANIONPressmeddelande2026-10-08 08:00

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, will be attending and presenting at several investor, Life Science and Scientific conferences during the remaining part of 2026.

Below an overview of places where you can currently meet Saniona and hear more about our programs and strategy.
Please also visit our website www.saniona.com for an updated list of conferences Saniona will attend.

Investor & Life Science events:

Redeye – Neurology event October 15 – Stockholm

Biostock – Life science summit November 4-5 – Lund

BIO-Europe November 9-11 – Cologne

Aktieinfo November 24 – Kolding

DI Investor Summit – Life Science December 8 – Stockholm

Scientific conferences:

International League Against Epilepsy November 11-13 – Rome

Society for Neuroscience, annual meeting November 14-18 – Washington DC

International Pharmaco-EEG Society November 16-19 – Vilnius

AES (American Epilepsy Society) December 4-8 – Denver

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for pediatric epilepsy syndromes and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, and Argentina. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, Cephagenix and AstronauTx, which holds worldwide rights to ATX0926. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.